QUADIRA BIOSCIENCES AG was incorporated on 17 March 2021 and has its registered seat in Solothurn,Switzerland.

QUADIRA BIOSCIENCES AG was founded on March 17, 2021, and is based in Solothurn, Switzerland. QUADIRA BIOSCIENCES AG, a joint venture between Anfass Life Technologies AG and Xlife Sciences AG, leverages the technologies of abc biopply and Veraxa to improve antibody-drug conjugates (ADCs) for the treatment of oncological indications. The combination of both technologies enables the company to develop innovative, highly effective ADCs with higher cytotoxic activity and simultaneously improved side effect profiles for cancer therapy in a significantly shortened preclinical phase, largely avoiding the need for animal testing.

‍